as 12-18-2024 9:55am EST
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.
Founded: | 1997 | Country: | United Kingdom |
Employees: | N/A | City: | N/A |
Market Cap: | 4.4M | IPO Year: | 2017 |
Target Price: | $25.00 | AVG Volume (30 days): | 99.0K |
Analyst Decision: | Buy | Number of Analysts: | 2 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -15.59 | EPS Growth: | N/A |
52 Week Low/High: | $1.20 - $19.40 | Next Earning Date: | 11-25-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
NCNA Breaking Stock News: Dive into NCNA Ticker-Specific Updates for Smart Investing
GlobeNewswire
23 days ago
MT Newswires
a month ago
GlobeNewswire
a month ago
GuruFocus.com
2 months ago
GlobeNewswire
3 months ago
Zacks
3 months ago
MT Newswires
3 months ago
MT Newswires
3 months ago
The information presented on this page, "NCNA NuCana plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.